Three drugs tested together for brain and spinal cord lymphoma that came back
Original title: Pembrolizumab, Ibrutinib and Rituximab in PCNSL
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, so a lot is still unknown.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests three drugs used together in people whose brain lymphoma has returned.
Who this trial is for. This study is for people with primary central nervous system lymphoma that has come back. It tests three drugs used together: pembrolizumab, ibrutinib, and rituximab (or a biosimilar).
Where it stands. The trial has not reported results. It is looking at whether this mix of 3 drugs can treat this cancer. That answer is not in yet.
What this means, and what it doesn't
What it could mean: Someone whose lymphoma has come back may want to ask their care team about this study. The care team can say whether it fits their case.
What it doesn't mean: This does not mean the drug mix works. A trial is a test, not a proven treatment. Joining one is not a promise of help. It is not a cure.
Source: ClinicalTrials.gov, October 21, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.